HUNTSVILLE, Ala. (WHNT) – You’ve probably heard a friend or celebrity talk about IV therapy and how they feel amazing after receiving it. But what is it, and what are the health benefits? Located in ...

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.

SOLV readies Q4 results amid solid momentum, tariff headwinds, and M&A focus as investors watch margins and growth trends closely.

IV therapy ...

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 ...

At week 140, 80.8% of those administered guselkumab achieved clinical remission.

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...

DMT therapy significantly reduced major depressive disorder symptoms in a phase IIa trial. Learn more about this rapid-acting ...

Background Invasive coronary function testing (CFT) is indicated in patients with refractory angina with non-obstructed coronary arteries (ANOCA). Despite this, questions remain regarding patient ...

40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are ...

Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus QIDP Designation provides for five years of market exclusivity ...

Treatment with systemic intravenous olvimulogene nanivacirepvec (Olvi-Vec) led to promising preliminary results in patients ...